NCT05532696View on ClinicalTrials.gov

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

September 27, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

May 31, 2027

Conditions
Advanced Solid TumorNon Small Cell Lung CancerHER2 Mutations
Interventions
DRUG

ABT-101

Patients will receive ABT-101 by oral administration on a 28-day cycle

Trial Locations (5)

10002

RECRUITING

National Taiwan University Hospital, Taipei

11031

RECRUITING

Taipei Medical Univresity Hospital, Taipei

33305

RECRUITING

Chang Gung Memorial Hospital, Linkou, Taoyuan District

40705

RECRUITING

Taichung Veterans General Hospital, Taichung

70403

RECRUITING

National Cheng Kung University Hospital, Tainan City

Sponsors
All Listed Sponsors
lead

Anbogen Therapeutics, Inc.

INDUSTRY

NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | Biotech Hunter | Biotech Hunter